Retension Pharmaceuticals, Inc. (RTSN)
10.69
-0.03
(-0.28%)
USD |
NASDAQ |
Nov 06, 10:17
Retension Pharmaceuticals Enterprise Value : 99.17M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | 99.17M |
| November 04, 2026 | 106.07M |
| November 03, 2026 | 107.60M |
| November 02, 2026 | 103.74M |
| October 30, 2026 | 104.22M |
| October 29, 2026 | 107.92M |
| October 28, 2026 | 117.85M |
| October 27, 2026 | 121.24M |
| October 26, 2026 | 126.91M |
| October 23, 2026 | 134.88M |
| October 22, 2026 | 136.85M |
| Date | Value |
|---|---|
| October 21, 2026 | 132.90M |
| October 20, 2026 | 142.21M |
| October 19, 2026 | 143.39M |
| October 16, 2026 | 125.58M |
| October 15, 2026 | 110.92M |
| October 14, 2026 | 106.42M |
| October 13, 2026 | 106.34M |
| October 12, 2026 | 103.90M |
| October 09, 2026 | 97.67M |
| October 08, 2026 | 109.26M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AbbVie, Inc. | 579.64B |
| Abeona Therapeutics, Inc. | 96.80M |
| America Great Health | 5.128M |
| Acumen Pharmaceuticals, Inc. | -36.83M |
| Aardvark Therapeutics, Inc. | -48.90M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.171M |
| Total Expenses (Quarterly) | 4.171M |
| EPS Diluted (Quarterly) | -0.5292 |
| Earnings Yield | -11.17% |
| Normalized Earnings Yield | -11.17 |